Innovating oncology treatments
Avenzoar Pharmaceuticals is a pioneering pre-clinical pharmaceutical company specialized in developing innovative small molecule therapeutics targeting mechanisms of metastasis and drug resistance. Our focus is on creating novel therapies that address unmet medical needs in cancer treatment. Avenzoar has a dedicated mission to bring new hope to patients through groundbreaking cancer treatments.
Our mission
Through cutting-edge research and development, we advance the science of oncology and improve patient outcomes, with a primary focus on treating recalcitrant cancers, including pancreatic and ovarian cancer, by inhibiting metastasis and chemo-resistance mechanisms.
A promising new therapy
Our leading investigational drug represents a significant advancement in the treatment of cancer. AP-001 has shown promising results in preclinical studies. The company has prepared a pre-IND briefing book and is expected to engage with the US FDA in early 2026, with anticipated clinical trials to demonstrate AP-001 efficacy and safety in pancreatic cancer patients beginning in 2027.
AI-Enabled Precision Oncology
Avenzoar integrates advanced AI and multi-modal data to accelerate discovery and personalize therapy for cancer patients. Our AI systems identify novel molecular and morphological signatures across tumor biology and treatment response, enabling insights that go beyond individual data types.
Predictive outcome & treatment response
Using proprietary multi-modal models, we assess tumor aggressiveness, forecast response to therapies, and prioritize intervention strategies.
Pan-cancer foundational models
Our core AI models train on diverse cancer datasets, extracting cross-tumor morphologic and molecular features that strongly correlate with clinical outcomes.
Rapid insight, minimal biopsy
Unlike conventional assays requiring extensive tissue and long turnaround times, our AI-enabled analyses deliver insights within hours while preserving precious biopsy material.
Expert highlight
Dr. Stephen Pandol
Avenzoar President, CMO & Co-Founder